SBFI-26

Names

[ Name ]:
SBFI-26

Biological Activity

[Description]:

SBFI-26 is a selective and competitive inhibitor of fatty acid binding proteins FABP5 and FABP7, with Kis of 0.9 µM and 0.4 µM for FABP5 and FABP7, respectively. SBFI-26 produces anti-nociceptive and anti-inflammatory effects[1][2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Metabolic Enzyme/Protease >> FABP

Research Areas >> Neurological Disease

[Target]

Ki: 0.9 μM (FABP5), 0.4 µM (FABP7)[1][2]

[In Vitro]

SBFI-26 binds to the canonical ligand-binding pocket of FABP5[1]. SBFI-26 significantly inhibits cellular AEA accumulation[2].

[In Vivo]

SBFI-26 (20 mg/kg, i.p.) significantly reduces carrageenan-induced thermal hyperalgesia and paw edema[2]. SBFI-26 produces antinociceptive and anti-inflammatory effects in mice[2]. Animal Model: Mice[2] Dosage: 20 mg/kg Administration: Intraperitoneal injection Result: Significantly reduced carrageenan-induced thermal hyperalgesia and paw edema.

[References]

[1]. Berger WT, et al. Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One. 2012;7(12):e50968.

[2]. Hsu HC, et al. The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites. Biochemistry. 2017 Jul 11;56(27):3454-3462.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₈H₂₂O₄

[ Molecular Weight ]:
422.47

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.